Guideline-Directed Medical Therapy Attainment and Outcomes in Dialysis-Requiring Versus Nondialysis Chronic Kidney Disease in the ISCHEMIA-CKD Trial.
cardiovascular diseases
clinical trial
kidney
lipoproteins
secondary prevention
Journal
Circulation. Cardiovascular quality and outcomes
ISSN: 1941-7705
Titre abrégé: Circ Cardiovasc Qual Outcomes
Pays: United States
ID NLM: 101489148
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
pubmed:
5
10
2022
medline:
21
10
2022
entrez:
4
10
2022
Statut:
ppublish
Résumé
Patients with chronic kidney disease (CKD) on dialysis (CKD G5D) have worse cardiovascular outcomes than patients with advanced nondialysis CKD (CKD G4-5: estimated glomerular filtration rate <30 mL/[min·1.73m This was a subgroup analysis of ISCHEMIA-CKD (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease) participants with CKD G4-5 or CKD G5D and moderate-to-severe myocardial ischemia on stress testing. Exposures included dialysis requirement at randomization and GDMT goal achievement during follow-up. The composite outcome was all-cause mortality or nonfatal myocardial infarction. Individual GDMT goal (smoking cessation, systolic blood pressure <140 mm Hg, low-density lipoprotein cholesterol <70 mg/dL, statin use, aspirin use) trajectory was modeled. Percentage point difference was estimated for each GDMT goal at 24 months between CKD G5D and CKD G4-5, and for association with key predictors. Probability of survival free from all-cause mortality or nonfatal myocardial infarction by GDMT goal achieved was assessed for CKD G5D versus CKD G4-5. A total of 415 CKD G5D and 362 CKD G4-5 participants were randomized. Participants with CKD G5D were less likely to receive statin (-6.9% [95% CI, -10.3% to -3.7%]) and aspirin therapy (-3.0% [95% CI, -5.6% to -0.6%]), with no difference in other GDMT goal attainment. Cumulative exposure to GDMT achieved during follow-up was associated with reduction in all-cause mortality or nonfatal myocardial infarction (hazard ratio, 0.88 [95% CI, 0.87-0.90]; per each GDMT goal attained over 60 days), irrespective of dialysis status. CKD G5D participants received statin or aspirin therapy less often. Cumulative exposure to GDMT goals achieved was associated with lower incidence of all-cause mortality or nonfatal myocardial infarction in participants with advanced CKD and chronic coronary disease, regardless of dialysis status. URL: https://www. gov; Unique identifier: NCT01985360.
Sections du résumé
BACKGROUND
Patients with chronic kidney disease (CKD) on dialysis (CKD G5D) have worse cardiovascular outcomes than patients with advanced nondialysis CKD (CKD G4-5: estimated glomerular filtration rate <30 mL/[min·1.73m
METHODS
This was a subgroup analysis of ISCHEMIA-CKD (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease) participants with CKD G4-5 or CKD G5D and moderate-to-severe myocardial ischemia on stress testing. Exposures included dialysis requirement at randomization and GDMT goal achievement during follow-up. The composite outcome was all-cause mortality or nonfatal myocardial infarction. Individual GDMT goal (smoking cessation, systolic blood pressure <140 mm Hg, low-density lipoprotein cholesterol <70 mg/dL, statin use, aspirin use) trajectory was modeled. Percentage point difference was estimated for each GDMT goal at 24 months between CKD G5D and CKD G4-5, and for association with key predictors. Probability of survival free from all-cause mortality or nonfatal myocardial infarction by GDMT goal achieved was assessed for CKD G5D versus CKD G4-5.
RESULTS
A total of 415 CKD G5D and 362 CKD G4-5 participants were randomized. Participants with CKD G5D were less likely to receive statin (-6.9% [95% CI, -10.3% to -3.7%]) and aspirin therapy (-3.0% [95% CI, -5.6% to -0.6%]), with no difference in other GDMT goal attainment. Cumulative exposure to GDMT achieved during follow-up was associated with reduction in all-cause mortality or nonfatal myocardial infarction (hazard ratio, 0.88 [95% CI, 0.87-0.90]; per each GDMT goal attained over 60 days), irrespective of dialysis status.
CONCLUSIONS
CKD G5D participants received statin or aspirin therapy less often. Cumulative exposure to GDMT goals achieved was associated with lower incidence of all-cause mortality or nonfatal myocardial infarction in participants with advanced CKD and chronic coronary disease, regardless of dialysis status.
REGISTRATION
URL: https://www.
CLINICALTRIALS
gov; Unique identifier: NCT01985360.
Identifiants
pubmed: 36193750
doi: 10.1161/CIRCOUTCOMES.122.008995
pmc: PMC9588677
mid: NIHMS1832481
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Cholesterol, LDL
0
Aspirin
R16CO5Y76E
Banques de données
ClinicalTrials.gov
['NCT01985360']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e008995Subventions
Organisme : NHLBI NIH HHS
ID : U01 HL105907
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL117904
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL117905
Pays : United States
Références
J Am Soc Hypertens. 2018 Mar;12(3):154-181
pubmed: 29396103
Circ Cardiovasc Qual Outcomes. 2019 Nov;12(11):e006002
pubmed: 31718297
Am Heart J. 2018 Nov;205:42-52
pubmed: 30172098
Ann Intern Med. 2021 Mar;174(3):385-394
pubmed: 33166222
Kidney Int. 2020 Oct;98(4):839-848
pubmed: 32653403
Hypertension. 2017 Feb;69(2):314-322
pubmed: 28028192
Am J Kidney Dis. 2015 Nov;66(5):884-930
pubmed: 26498416
Lancet. 2011 Jun 25;377(9784):2181-92
pubmed: 21663949
Lancet Diabetes Endocrinol. 2016 Oct;4(10):829-39
pubmed: 27477773
J R Stat Soc Ser C Appl Stat. 2018 Jan;67(1):145-163
pubmed: 29277843
Ann Transl Med. 2016 Jan;4(2):30
pubmed: 26889483
N Engl J Med. 2005 Jul 21;353(3):238-48
pubmed: 16034009
N Engl J Med. 2020 Apr 23;382(17):1608-1618
pubmed: 32227756
N Engl J Med. 2009 Apr 2;360(14):1395-407
pubmed: 19332456
N Engl J Med. 2010 Apr 29;362(17):1575-85
pubmed: 20228401
J Am Coll Cardiol. 2018 Nov 6;72(19):2297-2305
pubmed: 30384885
Phys Sportsmed. 1994 Nov;22(11):45-55
pubmed: 29275663
Ann Intern Med. 2014 Feb 4;160(3):182
pubmed: 24323134
BMJ Open. 2018 May 8;8(5):e019950
pubmed: 29739781
J Am Heart Assoc. 2018 Jun 9;7(12):
pubmed: 29886420
Stat Med. 2003 Mar 15;22(5):795-809
pubmed: 12587106
J Am Coll Cardiol. 2015 Aug 18;66(7):765-773
pubmed: 26271057
J Am Soc Nephrol. 2021 Mar;32(3):663-675
pubmed: 33547215
JAMA. 2002 Nov 20;288(19):2421-31
pubmed: 12435255
N Engl J Med. 2008 Feb 7;358(6):580-91
pubmed: 18256393
JAMA Intern Med. 2017 Oct 1;177(10):1498-1505
pubmed: 28873137
Am Heart J. 2006 Mar;151(3):745-53
pubmed: 16504645
J Am Soc Nephrol. 2017 Sep;28(9):2812-2823
pubmed: 28642330
N Engl J Med. 2015 Nov 26;373(22):2103-16
pubmed: 26551272